ASHLEIGH GARZA: Open Payments
NPI 1861922676 · GRANBURY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$437 in 21 payments from 13 companies in 2025. Trend: 2023 $1,439 · 2024 $1,596 · 2025 $437
Food & beverage: $437
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 4 | $87 |
| Novartis Pharmaceuticals Corporation | 3 | $71 |
| Abbott Laboratories | 2 | $43 |
| Exact Sciences Corporation | 2 | $38 |
| Amgen Inc. | 2 | $28 |
| Boston Scientific Corporation | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
Products named: XTAMPZA, LEQVIO, PROCLAIM, Cologuard Collection Kit, OTEZLA, Intracept, REXULTI, RELISTOR.
Industry payments across TX — which companies pay providers there.
